- On track towards Vision 2030
- Solid revenue growth of 17% on the back of Line 3 in CDMO sterile Injectables
- EBITDA margins to expand going forward as production stabilizes at Montreal facility and revenue ramps up at Spokane facility of CDMO Sterile Injectables business
Bangalore : The Board of Jubilant Pharmova Limited met today to approve financial results for the quarter and nine months ended Dec 31, 2025.
| Particulars (Rs. Cr.) | Q3’FY25 | Q2’FY26 | Q3’FY26 | Y-o-Y | 9M’FY25 | 9M’FY26 | Y-o-Y |
| Revenue | 1,822 | 1,966 | 2,123 | 17% | 5,306 | 5,990 | 13% |
| Total Income | 1,831 | 1,976 | 2,143 | 17% | 5,351 | 6,032 | 13% |
| EBITDA | 296 | 351 | 310 | 5% | 873 | 963 | 10% |
| EBITDA Margin (%) | 16.20% | 17.80% | 14.50% | (172) bps | 16.30% | 16.00% | (36) bps |
| Normalised PAT1 | 104 | 124 | 86 | -17% | 277 | 313 | 13% |
| Normalised PAT Margin | 5.70% | 6.30% | 4.00% | (168) bps | 5.20% | 5.20% | 2 bps |
1. Normalised PAT is after adjusting for exceptional items and corresponding tax.
Commenting on the Company’s performance in Q3’FY26, Mr. Shyam S Bhartia, Chairman Jubilant Pharmova Limited and Mr. Hari S Bhartia, Co-Chairman & Non-Executive Director, Jubilant Pharmova Limited said, “We are pleased to announce revenue of Rs. 2,123 Cr. for Q3’FY26, which reflects a solid growth of 17% on YoY basis. Revenue growth is particularly driven by incremental revenue generation from the new & third line in CDMO Sterile Injectable business. We expect this growth momentum to continue as we make progress in the last quarter of current financial year. EBITDA for the period grew by 5% YoY to Rs. 310 Cr. due to improved performance in CDMO Sterile Injectables and CRDMO business. Normalised PAT for the quarter stood at Rs. 86 Cr. As we are consciously investing in Radiopharma, CDMO Sterile Injectables and CRDMO business to secure future growth, Net Debt / EBITDA remains range bound at 1.3x in Dec’25, lower from 1.5x in Sep’25.
During Q3’FY26, we saw exceptional growth momentum in the Ruby-Fill® installs. In the Allergy Immunotherapy business, we witnessed increase in demand from the US market. In the CDMO Sterile Injectables business, we ramped up revenue generation from technology transfer programs at Line 3 in Spokane. In the CRDMO business, we continue to invest in building CDMO capabilities. In the Generics business, we are foreseeing growth & profitability improvement. Lastly, in our Proprietary Novel drugs business, we continue to make progress in JBI-802 and JBI-778 clinical trials.
During the quarter, we witnessed a decline in EBITDA margins, primarily due to the temporary shutdown of our CDMO Sterile Injectables facility in Montreal for remediation following FDA observations. Production has resumed at our Montreal site in Q4’FY26. We anticipate EBITDA margins to strengthen going forward, effectively offsetting higher depreciation costs and driving net profit growth.”
9M’FY26 Financial Highlights
- Revenue grew by 13% on a YoY basis to Rs. 5,990 Cr. on the back of growth in revenue across all business segments.
- EBITDA grew by 10% on a YoY basis to Rs. 963 Cr. due to improved performance across all business segments.
- Normalised PAT increased by 13% on a YoY basis to Rs. 313 Cr. on the back of improved operating performance and reduced finance cost. Reported PAT in 9M’FY25 at Rs. 685 Cr. was higher because of one-time net exceptional income of Rs. 382 Cr.
Leave a Reply